Product Description: XY221 (Compound 16o) selectively inhibits BRD4 BD2, with an IC50 of 5.8 nM. XY221 demonstrates high pan-BD2 selectivity (667-fold over BRD4 BD1) and BRD4 BD2 domain selectivity (9−32-fold over BRD2/3/T BD2). XY221 induce Apoptosis in MV4-11 cells and shows anticancer activity [1].
Applications: Cancer-Kinase/protease
Formula: C32H34FN3O5
References: [1]Tong JB, et al. Discovery of novel BRD4-BD2 inhibitors via in silico approaches: QSAR techniques, molecular docking, and molecular dynamics simulations. Mol Divers. 2024 Apr;28(2):671-692.
Molecular Weight: 559.63
Research Area: Cancer
Target: AMPK;Apoptosis;Bcl-2 Family;c-Myc;Epigenetic Reader Domain;PAK